XML 42 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
USD ($)
RevenueStream
$ / shares
Jun. 30, 2017
USD ($)
$ / shares
Jun. 30, 2018
USD ($)
RevenueStream
$ / shares
Jun. 30, 2017
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
Condensed Consolidated Balance Sheets [Abstract]          
Current portion of deferred revenue $ 35,713   $ 35,713   $ 58,192
Long-term portion of deferred revenue 5,839   5,839   12,501
Accumulated deficit (387,894)   (387,894)   (296,221)
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]          
Revenue 18,321 $ 5,713 35,429 $ 11,807  
Loss from operations (63,423) (19,689) (93,750) (83,065)  
Net loss (62,046) (20,359) (91,673) (84,214)  
Condensed Consolidated Statement of Cash Flows [Abstract]          
Net loss (62,046) (20,359) (91,673) (84,214)  
Adjustments to reconcile net loss to net cash provided by operating activities:          
Deferred revenue     (29,141) 63,193  
Cash, cash equivalents at beginning of period     58,367 7,857  
Cash and cash equivalents 216,840 75,445 216,840 75,445  
Preferred Stock [Member]          
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]          
Net loss $ 0 $ (20,359) $ 0 $ (84,214)  
Net loss per share, basic and diluted (in dollars per share) | $ / shares $ 0 $ (0.70) $ 0 $ (2.92)  
Condensed Consolidated Statement of Cash Flows [Abstract]          
Net loss $ 0 $ (20,359) $ 0 $ (84,214)  
Research and Development Under Collaborative Agreement [Member]          
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]          
Revenue $ 18,321 5,713 $ 35,429 11,807  
Novartis [Member]          
Summary of Significant Accounting Policies [Abstract]          
Number of revenue streams | RevenueStream 1   1    
Novartis [Member] | Research and Development Under Collaborative Agreement [Member]          
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]          
Revenue $ 18,300 5,700 $ 35,400 11,800  
As Originally Reported Under Topic 605 [Member] | ASU 2014-09 [Member]          
Condensed Consolidated Balance Sheets [Abstract]          
Current portion of deferred revenue         50,579
Long-term portion of deferred revenue         8,306
Accumulated deficit         (284,413)
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]          
Loss from operations   (11,274)   (71,147)  
Net loss   (11,944)   (72,296)  
Condensed Consolidated Statement of Cash Flows [Abstract]          
Net loss   (11,944)   (72,296)  
Adjustments to reconcile net loss to net cash provided by operating activities:          
Deferred revenue       51,275  
Cash, cash equivalents at beginning of period       7,857  
Cash and cash equivalents   $ 75,445   $ 75,445  
As Originally Reported Under Topic 605 [Member] | ASU 2014-09 [Member] | Preferred Stock [Member]          
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]          
Net loss per share, basic and diluted (in dollars per share) | $ / shares   $ (0.41)   $ (2.50)  
As Originally Reported Under Topic 605 [Member] | ASU 2014-09 [Member] | Research and Development Under Collaborative Agreement [Member]          
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]          
Revenue   $ 14,128   $ 23,725  
Effect of Change [Member] | ASU 2014-09 [Member]          
Condensed Consolidated Balance Sheets [Abstract]          
Current portion of deferred revenue         7,613
Long-term portion of deferred revenue         4,195
Accumulated deficit         $ (11,808)
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]          
Loss from operations   (8,415)   (11,918)  
Net loss   (8,415)   (11,918)  
Condensed Consolidated Statement of Cash Flows [Abstract]          
Net loss   (8,415)   (11,918)  
Adjustments to reconcile net loss to net cash provided by operating activities:          
Deferred revenue       11,918  
Cash, cash equivalents at beginning of period       0  
Cash and cash equivalents   $ 0   $ 0  
Effect of Change [Member] | ASU 2014-09 [Member] | Preferred Stock [Member]          
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]          
Net loss per share, basic and diluted (in dollars per share) | $ / shares   $ (0.29)   $ (0.42)  
Effect of Change [Member] | ASU 2014-09 [Member] | Research and Development Under Collaborative Agreement [Member]          
Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]          
Revenue   $ (8,415)   $ (11,918)